Caladrius Biosciences (NASDAQ:CLBS) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.36) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.20, Fidelity Earnings reports.
Shares of NASDAQ:CLBS traded down $0.68 during midday trading on Friday, reaching $4.53. The company’s stock had a trading volume of 21,628 shares, compared to its average volume of 36,147. The company has a market cap of $47.56 million, a P/E ratio of -2.54 and a beta of 1.22. Caladrius Biosciences has a 1 year low of $2.91 and a 1 year high of $11.65.
A number of equities analysts have recently weighed in on CLBS shares. HC Wainwright boosted their price target on Caladrius Biosciences to $15.00 and gave the stock a “buy” rating in a report on Monday, September 10th. Chardan Capital reissued a “buy” rating on shares of Caladrius Biosciences in a report on Wednesday, August 29th. Finally, Zacks Investment Research raised Caladrius Biosciences from a “hold” rating to a “buy” rating and set a $6.25 price target for the company in a report on Wednesday, September 12th.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease.
Featured Article: Capital gains and your 401(k) or IRA
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.